/C O R R E C T I O N -- The Galien Foundation/

Rhea-AI Summary

The Galien Foundation issued a corrected announcement naming the 2026 Prix Galien USA nominees for four categories: Best Digital Health Solution, Best Medical Technology, Incubators, Accelerators and Equity, and Best Startup. Winners will be honored on October 29, 2026 at the American Museum of Natural History in New York City.

The update specifies that Future Doctor Inc has been added to the Best Digital Health Solution nominees for its MedGPT – AI Digital Twin of Doctors. The release also highlights the award criteria, global reach of the Prix Galien, and the high-profile 2026 awards committee.

Market Context

RA Capital Management, L.P. +3 joint filers recorded net buying in the platform's recent insider dat...

Analysis

RA Capital Management, L.P. +3 joint filers recorded net buying in the platform's recent insider data, adding an ownership signal to Hemab's nomination. Short positioning was categorized as low; clinical execution remained outside this announcement.

Key Figures

Award year: 2026 Award history: 20 years Awards ceremony date: October 29, 2026 +5 more

8 metrics

Award year 2026 Prix Galien USA nominees

Award history 20 years Prix Galien USA Awards

Awards ceremony date October 29, 2026 Prix Galien USA Awards Ceremony

FDA approval window last five years Best Medical Technology qualification

Global chapters 16 chapters Prix Galien organization

Country reach more than 75 countries Prix Galien organization

Foundation launch year 2025 Prix Galien Bridges Forum and Awards Ceremony

Prix Galien founding reference 1895 Alfred Nobel's last will and testament

Historical Context

5 past events · Latest: Aug 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Q2 earnings report	Positive	+3.8%	Cash resources supported operations into 2029 alongside pipeline progress.
Jul 14	Clinical data update	Positive	+9.6%	Phase 2 data showed sustained bleed reductions and FDA Phase 3 endorsement.
Jul 12	Clinical data update	Positive	+0.0%	HMB-002 produced biomarker increases and zero treated bleeds in most evaluable patients.
Jun 26	Pipeline presentation notice	Neutral	+16.8%	Hemab announced nine pipeline updates scheduled for the ISTH Congress.
May 27	Conference participation notice	Neutral	+2.7%	Hemab scheduled a fireside chat at the Jefferies healthcare conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior five news events produced positive or flat 24-hour reactions, with the strongest gains following pipeline and clinical updates.

Key Terms

fda approved, leadless pacemaker system, transcatheter mitral valve replacement, pharmacology

4 terms

fda approved regulatory

"must be U.S. Food and Drug Administration (FDA) approved for marketing"

FDA approved means the U.S. Food and Drug Administration has reviewed evidence and authorized a drug, vaccine, medical device, or diagnostic for specific use because it met standards for safety and effectiveness. For investors, approval is like a product passing a stringent safety inspection or receiving a business license: it clears a major regulatory hurdle, allows marketing and sales for the approved use, and materially reduces regulatory risk while often unlocking revenue and valuation potential.

leadless pacemaker system medical

"AVEIR™ Dual Chamber (DR) Leadless Pacemaker System"

An implantable cardiac device that paces the heart without the traditional insulated wires (leads); it is a small capsule placed directly inside a heart chamber via a catheter, rather than being connected by wires to a pocket under the skin. It matters to investors because it represents a technological shift in cardiac device markets—changing procedural settings, complication profiles, replacement patterns and reimbursement dynamics—factors that can affect manufacturers’ sales, profit margins and adoption rates.

transcatheter mitral valve replacement medical

"Transcatheter Mitral Valve Replacement System"

A minimally invasive heart procedure that replaces a failing mitral valve by delivering a new valve on a thin tube (catheter) through blood vessels rather than open‑chest surgery. Think of it like swapping a worn gate from inside a building without tearing down the wall. It matters to investors because its adoption, regulatory approvals, clinical outcomes and reimbursement shape markets for medical devices, hospital demand and company revenues in the cardiac care sector.

pharmacology medical

"the father of medical science and modern pharmacology"

Pharmacology is the science of how drugs affect the body and how the body affects drugs — including what a drug does, how much is needed, how long it lasts, and possible side effects. For investors, pharmacology matters because it determines whether a medicine is likely to work safely, how it will be dosed, what risks regulators and doctors will see, and therefore how big its market and approval chances might be — like testing a recipe to see if it will reliably satisfy customers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

In the news release, The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup", issued 13-Aug-2026 by The Galien Foundation over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"

Celebrating 20 Years of Honoring the Digital Breakthroughs, Pioneering Startups, and Ecosystems Driving the Future of Healthcare

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, announced today the 2026 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup." Winners will be honored during the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.

"Witnessing the incredible momentum in medical technology, digital health, and startup ventures is inspiring," said Kenneth C. Frazier, Co-Chair of the Galien Forum, Prix Galien USA Awards Committee. "As we celebrate two decades of the Prix Galien USA Awards, we look forward to honoring this new class of nominees whose inventive work epitomizes the future of health and our collective commitment to improving lives through scientific brilliance."

Marking two decades of shaping medicine for patients worldwide, The Galien Foundation continues to inspire spirited collaboration between science and industry leaders on the most critical topics in medical technology, entrepreneurship, and equity.

"We applaud this year's remarkable Prix Galien USA nominees as we mark twenty years of excellence in medical technology, digital health, and entrepreneurship," said Bruno Cohen, Chairman of The Galien Foundation. "Their achievements beautifully demonstrate how scientific advancements can transform human lives and improve the wellbeing of our planet."

To qualify, each candidate must demonstrate tremendous potential to improve human health and for "Best Medical Technology" must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years. Sales data are not considered by the nominating committee in their award nominee selection, only science and health impact.

The following candidates have been selected as the 2026 Prix Galien USA nominees:

Best Digital Health Solution (Nominees)

Accumulus Technologies	Accumulus Platform
AEYE Health	AEYE-DS (AEYE Diagnostic Screening)
Altis Labs, Inc.	Imaging-based Prognostication (IPRO)
Aptar Digital Health	Migraine Buddy: a digital health solution generating insights from user-reported data and continuous biometrics
Ayble Health	Ayble: AI-Enabled Virtual Specialty GI Clinic
Beaconcure	Verify: AI-Enabled Statistical Analysis Platform
Biorce	Aika
Cleerly	Cleerly LABS
Evidation Health	Event-Triggered Flare-State Proteomics Platform and Autoimmune Cohort
Evinova	Unified Trial Solution
Fasikl	Felix NeuroAI Wristband
Future Doctor Inc	MedGPT - AI Digital Twin of Doctors
Gheorg	Mental Health App Democratizing Therapy Support for Children
Helfie AI	Helfie AI
Intellect	Intellect: Clinically Validated AI-enabled Global Mental Healthcare Platform
Life365	CloudCare
Medable	Medable Agentic Clinical Development Platform
MPA	MyPsychAdmin
OpenEvidence Inc.	OpenEvidence
Owkin	K Pro
PHIL Inc.	PHIL Digital Hub & PHIL Direct
RapidAI	Rapid Navigator Pro™
SamaCare	SamaCare Platform
The TeleDentists	The TeleDentists
Welldoc	The Welldoc Platform: Healthcare-Ready AI

Best Medical Technology (Nominees)

Abbott	AVEIR™ Dual Chamber (DR) Leadless Pacemaker System
Abbott	Esprit™ BTK Everolimus Eluting Resorbable Scaffold System
Abbott	TriClip™ G4 System
Alcon	UNITY® Vitreoretinal Cataract System (VCS)
Beyond Air, Inc.	LungFit® PH
Cochlear Limited (Cochlear North America)	Nucleus® Nexa™ System
Cresilon	TRAUMAGEL®
Edwards Lifesciences	Edwards SAPIEN M3 Transcatheter Mitral Valve Replacement System
Establishment Labs Holdings Inc.	Motiva Flora® SmoothSilk® Tissue Expander
Guardant Health	Guardant360® Liquid CDx
Guardant Health	Shield™
Insightec	Exablate® Neuro
Johnson & Johnson	INLEXZO™ (gemcitabine intravesical system)
Johnson & Johnson	Impella 5.5™ with SmartAssist™; Impella CP™ with SmartAssist™
Johnson & Johnson	Shockwave™ C2 Coronary IVL Catheter
Lumicell	LumiSystem™
Lungpacer Medical	AeroPace® Transvenous Diaphragm Neurostimulation System
MediBeacon Inc.	TGFR™ System
Medtronic	Altaviva™ Implantable Tibial Neuromodulation Device
Medtronic	Symplicity Spyral™ Renal Denervation System
MiniMed	MiniMed Go™ System
OUR United Corporation	TaiChiPro®
RefleXion Medical	RefleXion® X1 with SCINTIX® biology-guided radiotherapy

Incubators, Accelerators and Equity (Nominees)

ANDHealth (Australia)	ANDHealth+
Avant Bio	Avant Bio Fund II LP
Calibr-Skaggs Institute for Innovative Medicines	Calibr-Skaggs Drug Accelerator
Cross-Border Impact Ventures	Women's and Children's Health Technology Fund
Deep Knowledge Group (incorporating Deep Knowledge Ventures, Longevity Capital, Deep Knowledge Analytics, Deep Pharma Intelligence and Aging Analytics Agency) (https://www.dkv.global/)	Deep Knowledge Group - DeepTech for Social Good (investment, analytics and ecosystem-building consortium spanning AI, Longevity, BioTech and HealthTech)
Mayo Clinic	Mayo Clinic / Mayo Clinic and Arizona State University Alliance for Health Care Accelerator
McGill Dobson Centre for Entrepreneurship	McGill Dobson Centre for Entrepreneurship
Nucleate	The Activator
PureTech Health	PureTech Health
Start it @KBC	Start it @KBC
Weill Cornell Medicine BioVenture Elab	BioVenture eLab

Best Startup (Nominees)

ADVANCED BIODESIGN

AIVITA Biomedical, Inc.

Algen Biotechnologies, Inc.

Alloy Therapeutics

BigHat Biosciences

Bilix

BioSapien

Callio Therapeutics

Captor Therapeutics

Cellares

CheckUps COVA

Compass Pathways

Concordare Trials

Creative BioTherapeutics

EndoCyclic Therapeutics

EnPlusOne Bio

Faeth Therapeutics

General Oncology

HarborSite

Hemab Therapeutics (Nasdaq: COAG)

Hope Medicine

Iambic

Imaginostics, Inc.

Indapta Therapeutics

INGENIA Therapeutics Inc.

Innorna

Innova Therapeutics

Insilico Medicine

Intrepid Labs

Kapsule

LEAF4Life, Inc.

Leal Therapeutics

Leman Biotech Co., Ltd.

Libera Bio S.L.

LIFEN RESEARCH

Lipidio Pharma

magAssist Co., Ltd.

MAIA Biotechnology, Inc.

Mammoth Biosciences, Inc.

March Biosciences, Inc

Matrisome Bio, Inc.

Mesentech Inc.

META Pharmaceuticals Inc

Metro International Biotech, LLC

MirimGENE

Neurosterix

Noetik

Nona Biosciences

OncoRes Medical Pty Ltd

Outcomes4Me

OverT Bio

Paradigm Therapeutics

Pheast Therapeutics

Prellis Biologics, Inc

ProFound Therapeutics

Protara Therapeutics

Quercis

Regard

Rejuvenate Bio

Repair Biotechnologies, Inc.

ReST Therapeutics, Inc

RISA Labs

Rubedo Life Sciences, Inc.

SandboxAQ

Science Corporation

Sculpta, Inc.

SEED Therapeutics Inc.

Shenzhen ReeToo Biotechnology Co., Ltd.

Spore.Bio

Starton Therapeutics

Strand Therapeutics

Stream Biomedical, Inc.

SURGE Therapeutics

synseer

Tahoe Therapeutics

Transcend Therapeutics

Turbine

Ultrasound AI, Inc.

VarmX

Vascarta Inc.

VCCT Inc.

ViCardia Therapeutics, Inc.

XaTek Inc.

Zucara Therapeutics Inc.

Prix Galien Best Medical Technology, Best Digital Health Solution, Best Incubator / Accelerator / Equity, and Best Startup Committee 2026

Kenneth C. FRAZIER
Committee Chair, Former Chairman & CEO Merck

Roch DOLIVEUX
Honorary CEO, UCB

Dr. Mikael DOLSTEN
Former Chief Scientific Officer & President, Pfizer Research and Development

Alex GORSKY
Former CEO & Executive Chairman, Johnson & Johnson

Penny HEATON
M.D., Global Head, Office of the Chief Medical Officer, Johnson & Johnson

Sheri McCOY
Board of Directors, AstraZeneca, Former CEO, Avon

Joel S. MARCUS
Executive Chairman & Founder, Alexandria

Christophe WEBER,
Healthcare Executive, Former CEO Takeda Pharmaceutical

Elias ZERHOUNI
Former Head of Global R&D, Sanofi

About The Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Today, the Prix Galien operates through 16 chapters spanning more than 75 countries across Africa, the Americas, Asia, and Europe. Expansion is currently underway in China, Singapore, and Australia.

In 2025, the Foundation launched the inaugural Prix Galien Bridges Forum and Awards Ceremony at the Nobel Forum in Stockholm, spanning Northern and Southern Europe, Israel, and the Middle East, and the first-ever Patient Summit for Prix Galien USA, reinforcing its commitment to science without borders.

The Nobel Prize and the Prix Galien share a common birthplace in Paris, where Alfred Nobel signed his last will and testament in 1895. However, while the Nobel Prize in Physiology or Medicine recognizes up to three individuals for specific discoveries, the Prix Galien honors the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media: 
https://www.facebook.com/GalienFoundation/
https://twitter.com/GalienFdn 
https://www.linkedin.com/company/the-galien-foundation/ 

Media Contact: 
Kara Bradley
Finn Partners 
Kara.Bradley@finnpartners.com
646-213-7243

Correction:  Future Doctor Inc has been added to the list of Best Digital Health Solution nominees.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2026-prix-galien-usa-nominees-for-best-digital-health-solution-best-medical-technology-incubators-accelerators-and-equity-and-best-startup-302850770.html

SOURCE The Galien Foundation

FAQ

What correction did The Galien Foundation make in the August 13, 2026 Prix Galien USA nominees release?

The correction added Future Doctor Inc to the 2026 Prix Galien USA Best Digital Health Solution nominees. According to The Galien Foundation, Future Doctor Inc’s MedGPT – AI Digital Twin of Doctors is now included among the listed digital health candidates.

When and where will the 2026 Prix Galien USA Awards Ceremony take place?

The 2026 Prix Galien USA Awards Ceremony will be held on October 29, 2026 at the American Museum of Natural History in New York City. According to The Galien Foundation, this event will honor winners across four innovation-focused healthcare categories.

What are the 2026 Prix Galien USA award categories announced by The Galien Foundation?

The 2026 Prix Galien USA categories are Best Digital Health Solution, Best Medical Technology, Incubators, Accelerators and Equity, and Best Startup. According to The Galien Foundation, nominees in these categories are recognized for potential to significantly improve human health.

How does a medical technology qualify for nomination to the 2026 Prix Galien USA awards?

To qualify for Best Medical Technology, a candidate must be FDA-approved for marketing within the last five years. According to The Galien Foundation, the nominating committee considers only scientific merit and health impact, not sales data or commercial performance.

What role does Hemab Therapeutics (Nasdaq: COAG) play in the 2026 Prix Galien USA Best Startup category?

Hemab Therapeutics is listed as one of many nominees in the Best Startup category. According to The Galien Foundation, this category highlights emerging companies whose scientific work shows strong potential to improve human health, without implying any specific ranking or award outcome.

Who chairs the 2026 Prix Galien USA committee for Best Medical Technology and related categories?

The 2026 committee is chaired by Kenneth C. Frazier, former Chairman and CEO of Merck. According to The Galien Foundation, the committee also includes senior leaders and former executives from major global healthcare and biopharmaceutical companies such as Johnson & Johnson and Takeda.